Dabrafenib (Tafinlar)

Combination Therapy, Targeted TherapyApproved for: NSCLCBiomarker: BRAF Dabrafenib (Tafinlar) is a FDA-approved Targeted Therapy/Combination Therapy for non-small cell lung cancer that has metastasized (NSCLC) with the biomarker BRAF. It is used with trametinib. Dabrafenib is used only in patients...
|
May 31, 2021
|

Durvalumab (Imfinzi)

Combination TherapyApproved for: NSCLC Durvalumab (Imfinzi) is a FDA-approved Combination Therapy for Non-small cell lung cancer (NSCLC). It is used in adults with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum...
|
May 30, 2021
|

Nivolumab (Opdivo/Opdivo Injection)

Combination TherapyApproved for: SCLC Nivolumab (Opdivo/Opdivo Injection) is a FDA-approved CombinationTherapy for Small cell lung cancer (SCLC) that has metastasized. It is used in patients whose cancer got worse after treatment with platinum chemotherapy and at least one other...
|
May 30, 2021
|

Atezolizumab (Tecentriq)

Type of Treatment: Combination TherapyApproved for: NSCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used: With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line...
|
May 29, 2021
|

Atezolizumab (Tecentriq)

Combination TherapyApproved for: SCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for small cell lung cancer (SCLC). It is used with carboplatin and etoposide as first-line therapy in adults with extensive-stage cancer. Related Research News Novel drug shows promise in...
|
May 29, 2021
|

Atezolizumab (Tecentriq)

Combination TherapyApproved for: NSCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer (NSCLC). It is used: With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line therapy in adults with non-squamous non-small...
|
May 27, 2021
|

Durvalumab (Imfinzi)

Combination TherapyApproved for: SCLC Durvalumab (Imfinzi) is a FDA-approved treatment for small cell lung cancer (SCLC) in adults. It is used with etoposide phosphate and either carboplatin or cisplatin as first-line therapy in adults with extensive-stage disease. Related Research...
|
May 27, 2021
|